Results 81 to 90 of about 326,443 (336)
Advanced Materials Technologies, EarlyView.This review explores advances in wearable and lab‐on‐chip technologies for breast cancer detection. Covering tactile, thermal, ultrasound, microwave, electrical impedance tomography, electrochemical, microelectromechanical, and optical systems, it highlights innovations in flexible electronics, nanomaterials, and machine learning.
Neshika Wijewardhane +4 more
wiley +1 more source
Recommendations for HER2 testing in the UK [PDF]
, 2000 Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease.
Bartlett, J. +8 more
core +2 more sources
Research Progress in Wearable Microneedle Sensors for Health Analysis
Advanced Sensor Research, EarlyView.Wearable biosensors are transforming personal healthcare by enabling minimally invasive, molecular‐level monitoring. Emerging electrochemical microneedle sensors can detect analytes in interstitial fluid, enabling painless extraction and real‐time tracking.
Adnan Zameer +3 more
wiley +1 more source
Biomolecules, 2020 Human epidermal growth factor (HER2) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in breast cancer. Its increased level prognoses a poor patient outcome and a high mortality rate. Despite the widening spectrum of therapies
Beáta Biri-Kovács +5 more
doaj +1 more source
Advanced Science, EarlyView.This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang +15 more
wiley +1 more source
Breast Cancer: Targets and Therapy, 2023 Qianming Bai,1– 3,* Hong Lv,1– 3,* Longlong Bao,1– 3,* Yu Yang,1– 3 Xin Zhang,4 Heng Chang,1– 3 Tian Xue,1– 3 Min Ren,1– 3 Xiaoli Zhu,1– 3 Xiaoyan Zhou,1– 3,* Wentao Yang1– 3,* 1Department of Pathology, Fudan University Shanghai ...
Bai Q +10 more
doaj
Nanobody based dual specific CARs [PDF]
, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +2 more sources
Advanced Science, EarlyView.Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang +9 more
wiley +1 more source
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary [PDF]
, 2018 Breast Cancer (BC) skin metastases represent a challenging clinical scenario. Although they usually arise when other distant metastases are already present, they may also represent a form of locoregional recurrence (LRR). Systemic therapy in this setting
Dieci, Maria V +8 more
core +1 more source
Advanced Science, EarlyView.Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance +17 more
wiley +1 more source